CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Lorazepam Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2018-05-03. Latest FDA row update: 2026-09-22.
FDA lists 11 package records, with companies: Amphastar Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company, International Medication Systems, Limited. Package NDCs: 0409-1985-30, 0641-6000-10, 0641-6001-25, 0641-6002-10, 0641-6003-25, 0641-6044-25, 0641-6045-25, 0641-6046-10, 0641-6047-10, 65219-368-02, 76329-8261-1.
FDA shortage reason: Demand increase for the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | 76329-8261-1 | Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | Available | 2026-09-16 |
| Fresenius Kabi USA, LLC | 65219-368-02 | Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) | Unavailable | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6000-10 | Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6001-25 | Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) | Limited Availability | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6002-10 | Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6003-25 | Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6044-25 | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) | Limited Availability | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6046-10 | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6045-25 | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6047-10 | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) | Unavailable | 2026-09-18 |
| Hospira, Inc., a Pfizer Company | 0409-1985-30 | Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) | Limited Availability | 2026-09-22 |
Source facts
Grouped generic ingredient: Lorazepam Injection · 11 package records
Therapeutic categories: Neurology
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.